期刊文献+

国产吉西他滨联合铂类对晚期非小细胞肺癌患者生活质量的影响 被引量:2

Influences of china-made gemcitabine plus platinum regimen on the quality of life among patients with advanced non-small cell lung cancer
原文传递
导出
摘要 目的观察国产吉西他滨联合铂类治疗晚期非小细胞肺癌(NSCLC)的临床疗效,不良反应及生活质量。方法晚期NSCLC患者随机分为两组:吉西他滨联合卡铂(GC方案组),吉西他滨联合顺铂(GP方案组)。GC组采用吉西他滨1000 mg/m2,静脉滴注30 min,d1、8,卡铂300 mg/m2,d1;GP组采用顺铂30 mg/m2,d1~3,吉西他滨用法同GC组。每3周为1个周期。治疗2个周期评价疗效,每个周期评价不良反应。采用EORTC QLQ-C30和QLQ-LC13问卷对患者治疗前、后症状和生活质量进行评价,并对结果进行比较分析。结果总有效率、中位生存时间、中位疾病进展时间(TTP)、1年生存率、临床获益率两组对比差异无统计学意义(均P>0.05);两组主要不良反应为骨髓抑制和恶心呕吐,其中GC组反应较轻;两组生活质量各领域包括功能子领域及症状子领域评分治疗后明显改善,GC组改善更明显。结论吉西他滨联合铂类治疗晚期NSCLC疗效确切,两组化疗方案均能明显改善患者生活质量。其中GC方案耐受性更好,不良反应轻,在改善患者生活质量方面有一定的优势。 Objective To observe the clinical effect, toxicity and quality of life of gemcitabinc plus platinum regimen in treatment for advanced non-small cell lung cancer (NSCLC). Methods Advanced NSCLC patients were randomly divided into GC group which dripped intravenously gemcitabine (1000 mg/ m^2 ,d1 ,d8 ) and Carboplatin (dl), and GP group which dripped intravenously Cisplatin (30 mg/m^2 ,dl-d3 ) and gemcitabine( 1000 mg/m^2 ,dl ,d8). Three weeks of treatment were treated as one course, The toxicity was assessed after each course and the efficacy was evaluated per two courses. EORTC, QLQ-C30 and QLQ- LC13 questionnaires were employed to evaluate the changes of quality of life(QOL) and symptoms before and after treatment, and the evaluation results were compared and analyzed. Results There were no statistically significant differences between two groups in the total efficacy, median survival rate, median time to progres- sion( TIP), 1-year Survival Rate and Clinical Benefit Rate ( P 〉 0.05 ). The main toxic and side-effect were myelosuppression, nausea and vomiting, which were comparatively mild in GC group. The QOL, including function sub-field and symptom sub-field, were significantly improved after treatment in two groups, particularly in GC group. Conclusion The efficacy of gemcitabine plus platinum regimen in treatment of advanced NSCLC is significant. The QOL of patients were obviously improved in the two groups, however, GC group was slightly better in improving QOL, tolerance and adverse reactions.
出处 《中国肿瘤临床与康复》 2011年第6期484-488,共5页 Chinese Journal of Clinical Oncology and Rehabilitation
基金 首都医学发展基金联合攻关项目(2007-1049)
关键词 非小细胞肺 晚期 生活质量 化疗 Carcinoma, non-small cell lung Quality of life Advanced Chemotherapy
  • 相关文献

参考文献14

  • 1Jemal A,Tiwari RC,Murray T,et al.Cancer statistics,2004[J].CA Cancer J Clin,2004,54:8229-8241.
  • 2Sch iller JH,Harrington D,Belani CP,et al.Eastern Coopera-tive oncology Group.Comparison of four chemo therapy regimensfor advanced non-small cell lung cancer[J].N Engl J Med,2002,346:92-98.
  • 3Scarliotti GV,DeMarinis F,RinaldiM,et al.PhaseⅢrandom-ized trial comparing three platinum-based doublets in advancednon small cell lung cancer[J].J Clin Oncol,2002,20:4285-4291.
  • 4Toschi L,Finocch iaro G,Barto lini S,et al.Role of gemcit-abine in cancer therapy[J].Future Oncol,2005,1:7-17.
  • 5Manegold C.Gemcitabine(Gemzar)in non-small cell lung canc-er.Expert Rev Anticancer Ther,2004,4:345-360.
  • 6Rossi D,Graziano F,Catalano V,et al.A new cisplatin/gemcit-abine schedule in locally advanced(ⅢB)and metastatic(Ⅳ)non-small cell lung cancer:relationship between dose-intensityand efficacy.A phaseⅡstudy[J].Anticancer Res,2002,22:189-190.
  • 7熊建萍 张凌 钟陆行 等.国产吉西他联合卡铂治疗晚期非小细胞肺癌近期临床观察.中国肿瘤临床,2007,:857-859.
  • 8Zwitter M,Kovac V,Smrdel U,et al.PhaseⅠ-Ⅱtrial of low-dose gemcitabine in prolonged infusion and cisplatin for advancednon-small cell lung cancer[J].Anticaneer Drugs,2005,16:1129-1134.
  • 9Edelman MJ,Clark JI,Chansky K,et al.Randomized phaseⅡtrial of sequential chemotherapy in advanced non-small cell lungcancer(SWOG 9806):carboplatin/gemcitabine followed by pa-clitaxel or cisplatin/vinorelbine followed by docetaxel[J].ClinCancer Res,2004,10:5022-5026.
  • 10Wolfang S,Sylke N,Thomas B,et al.PhaseⅢstudy of second-line chemotherapy for advanced non-small-cell lung cancer withweekly compared with 3-weekly docetaxel[J].J Clin Oncol,2005,23:8389-8395.

二级参考文献35

  • 1潘振奎,张力,张星,王欣,李宁,徐菲,常建华,管忠震.中国非小细胞肺癌患者表皮生长因子受体突变的研究[J].癌症,2005,24(8):919-923. 被引量:44
  • 2管忠震,张力,李龙芸,蒋国梁,刘叙仪,储大同,赵洪云,李玮.吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究[J].癌症,2005,24(8):980-984. 被引量:114
  • 3周清华,王瑾,许峰.2005年美国国家综合癌症网(NCCN)非小细胞肺癌临床指南[J].中国肺癌杂志,2005,8(4):332-346. 被引量:75
  • 4张康,左强,罗荣城.吉非替尼治疗36例晚期非小细胞肺癌[J].中国癌症杂志,2006,16(10):878-879. 被引量:15
  • 5Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in ontology[J].J Natl Cancer Inst,1993,85(5) : 365- 376.
  • 6Stephens RJ, Hopwood P, Girling DJ. Defining and analyzing symptom palliation in cancer clinical trials: a deceptively difficult exercise [ J ] .Br J Cancer,1999,79(3-4) : 538-544.
  • 7Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer: a review of literature from 1970 to 1995 [ J ] . Chest,1998,113(2) : 467-481.
  • 8Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30[J].Qual Life Res,2000,9(2) : 129-137.
  • 9Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL1 Trial)[J].J Clin Oncol, 2003, 21 (12): 2237- 2246.
  • 10Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial [J].JAMA, 2003, 290 (16): 2149-2158.

共引文献137

同被引文献37

引证文献2

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部